{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-018018","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2026-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.117395+00:00","generated_at":"2026-05-15T05:21:57.329296+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aspire Biopharma closes $21M private placement, secures $22.5M credit facility for DCS acquisition","bullets":["Closed second tranche of $10M (12,500 preferred shares); total gross proceeds $21M from private placement.","Commitment letter for up to $22.5M senior secured credit facility to fund proposed $30M cash acquisition of DCS.","DCS (automotive supplier) had $200M+ revenue and $20M+ adjusted EBITDA in FY2025 (unaudited).","Stockholders' equity now exceeds $2.5M Nasdaq minimum; no new equity anticipated to consummate DCS purchase."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-018018","json":"https://secwatch.observer/filing/0001493152-26-018018.json","markdown":"https://secwatch.observer/filing/0001493152-26-018018.md","text":"https://secwatch.observer/filing/0001493152-26-018018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226018018/0001493152-26-018018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315226018018/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:21:57.329296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}